Cost effective prognostic assessment in IgAN- Quantitative.V2
Research type
Research Study
Full title
Can cost-effective strategies identify and stabilise higher risk patients with Immunoglobulin A Nephropathy and prevent end-stage renal disease?
IRAS ID
319709
Contact name
Michael Toal
Contact email
Sponsor organisation
Belfast Trust Research Governance Office
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This project aims to improve methods of identifying patients with IgAN who are at the highest risk and treating them earlier, to prevent the disease progressing to kidney failure and the associated economic losses.
We will examine the current methods of estimating the risk of kidney failure based on patient characteristics, the results of blood and urine tests and information gained by kidney biopsy examination. We aim to adapt and improve these models by improving the accuracy of testing to allow estimates to be made beyond the time of first diagnosis. This will provide patients with more accurate and up-to-date information about their condition at any time and will reduce costs by using tests and treatments more efficiently. Identifying the highest risk group and starting intensive treatment could reduce the rates of kidney failure and the requirement of expensive treatment such as dialysis.We aim to assess the costs of treating patients with IgAN and estimate how much money could be saved with more timely identification and deployment of treatments, therefore reducing the use of expensive therapies for kidney failure. This work will encourage investment in treatments that prevent kidney failure.
Overall this project aims to improve the care of people with IgAN by identifying and treating the highest risk patients to prevent kidney failure, reduce the amount of money spent by the health service and lost by individual patients.
REC name
HSC REC A
REC reference
23/NI/0015
Date of REC Opinion
3 Mar 2023
REC opinion
Further Information Favourable Opinion